论文部分内容阅读
Fluconazole是一个新的三氯杂茂类抗真菌药,药代动力学特征明显有别于酮康唑,能溶于水,可以口服和静脉注射给药,主要经肾消除。该药体外作用、疗效不如酮康唑,但是用动物模型对全身性白色念珠菌病的疗效则比酮康唑强。而且该药易透入脑脊液和眼,因此对真菌性脑膜炎和眼炎的疗效比酮康唑强。基于这些特点,作者对无白细胞减少症的深部真菌感染病人进行临床试验。
Fluconazole is a new trichloro-miscellaneous antifungal agent, pharmacokinetic characteristics are clearly different from ketoconazole, soluble in water, can be administered orally and intravenously, mainly by the kidney to eliminate. The drug in vitro, the effect is not as good as ketoconazole, but the animal model of systemic candidiasis is more effective than ketoconazole. And the drug easily penetrate cerebrospinal fluid and eyes, so the efficacy of fungal meningitis and ophthalmia than ketoconazole. Based on these characteristics, the authors conducted clinical trials of patients with deep fungal infections without leucopenia.